IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gravestock et al	Filed: Herewith				
Application No.: Not yet assigned	Attorney Docket No.: 100861-1P US				
Application No.: 10/536,686	Examiner: Not yet assigned				
Title: OXAZOLIDINONE AND/OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL					
AGENTS					

Mail Stop PCT Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, Applicant(s), wish to call the Examiner's attention to and make of record the references cited on the attached form(s) PTO-1449. All of the cited references were listed on the International Search Report, a copy of which is enclosed herewith for the convenience of the Examiner. Copies of the references are not being provided herewith because it is believed they were previously forwarded to the USPTO by the International Patent Bureau. Applicants are also enclosing a copy of the International Examination Report.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form.

Respectfully submitted,

Dated

Heidi Berven August 8, 2005

Reg. No.:

48,951

Phone No.:

1 781 839 4336

Enclosures:

Form 1449

International Search Report International Examination Report

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO				Complete if Known				
				Applica	ation Number	10/536,686		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			JRE [Filing Date		May 27, 2005		
				First Named Inventor		Michael Barry GRAVESTOCK		
				Art Unit		Not yet known		
				Examiner Name		Not yet known		
				Attorney Docket No. 100861-1P US				
			U.S. PATI	NT D	OCUMENTS			
Examiner	Cite			MM-DD-YYYY Applican		e of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Initials*	No.1					t of Cited Document		
/N.C./	US1	5,698,574	Decembe 16, 1997	Bayer Akt		iengesellschaft		
, , , , , , , , , , , , , , , , , , , ,			FOREIGN PA	ATENT	DOCUMENT	S		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (If known)			blication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т ⁸
				March 20,		ASTRAZENECA	1	
/N.C./	AA	WO 03/022824		20	-	ASTRAZENECA AB, ASTRAZENCA UK LIMITED		
/N.C./	AB	WO 01/94342			cember , 2001	DONG A PHARM CO LTD.,		
/N.C./	AC	EP 0 352 781 A		January 31, 1990		E.I. DU PONT DE NEMOURS AND COMPANY		
/N.C./	AD	WO 04/048350		June 10, 2004		ASTRAZENECA AB, ASTRAZENCA UK LIMITED		
/N.C./	AE	WO 04/048370		Jui 20	ne 10, 04	ASTRAZENECA AB, ASTRAZENCA UK LIMITED		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

/Nizal Chandrakumar/

Date

Considered

05/03/2008

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.